



RECEIVED

MAR 24 2003

TECH CENTER 1600/2900 Page 1 of 4

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1821.0020001/EKS/AJK	APPLICATION NO. 09/833,203
	APPLICANT Zauderer et al.	
	FILING DATE April 12, 2001	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
30	AA1	5,635,363	06/03/1997	Altman et al.	/	/	02/28/1995
↓	AB1	6,015,884	01/18/2000	Schneck et al.	/	/	03/28/1997
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
AS	AP1	AU-B-39005/89	02/01/1990	Australia	/	/	Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
20	AT	24	Abastado, J.-P., et al., "Dimerization of Soluble Major Histocompatibility Complex-Peptide Complexes Is Sufficient for Activation of T Cell Hybridoma and Induction of Unresponsiveness," J. Exp. Med. 182:439-447, The Rockefeller University Press (1995).

EXAMINER <i>W.D. G...</i>	DATE CONSIDERED 5-24-03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

MAR 24 2003

TECH CENTER 1600/2900
Page 2 of 4MAR 19 2003
PATENT & TRADEMARK OFFICE

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1821.0020001/EKS/AJK	APPLICATION NO. 09/833,203
	APPLICANT Zauderer et al.	
	FILING DATE April 12, 2001	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
fr	AL2	WO 93/10220	05/27/1993	WIPO			Yes No
	AM2	WO 96/26962	09/06/1996	WIPO			Yes No
	AN2	WO 97/35991	10/02/1997	WIPO			Yes No
	AO2	WO 99/11775	03/11/1999	WIPO			Yes No
	AP2	WO 99/13095	03/18/1999	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

fr	AR	25	Brusic, V., et al., "Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network," <i>Bioinformatics</i> 14:121-130, Oxford University Press (1998).
	AS	25	Dal Porto, J., et al., "A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations," <i>Proc. Natl. Acad. Sci. USA</i> 90:6671-6675, National Academy of Sciences (1993).
	AT	25	Daniel, S., et al., "Relationship Between Peptide Selectivities of Human Transporters Associated with Antigen Processing and HLA Class I Molecules," <i>J. Immunol.</i> 161:617-624, The American Association of Immunologists (1998).

EXAMINER <i>W. B. C. C.</i>	DATE CONSIDERED 5 20 03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



RECEIVED

MAR 24 2003

TECH CENTER 1000/2900

FORM PTO-1449 SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1821.0020001/EKS/AJK	APPLICATION NO. 09/833,203
	APPLICANT Zauderer et al.	
	FILING DATE April 12, 2001	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
<i>M</i>	AL3	WO 99/64464	12/16/1999	WIPO	—	—	Yes No
<i>L</i>	AM3	WO 00/00156	01/06/2000	WIPO	—	—	Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

<i>M</i>	AR	<u>26</u>	Ramakrishna, V., et al., "Generation and Phenotypic Characterization of New Human Ovarian Cancer Cell Lines with the Identification of Antigens Potentially Recognizable by HLA-Restricted Cytotoxic T Cells," <i>Int. J. Cancer</i> 73:143-150, Wiley-Liss, Inc. (1997).
<i>L</i>	AS	<u>26</u>	Robert, B., et al., "Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes," <i>Eur. J. Immunol.</i> 30:3165-3170, Wiley-VCH Verlag GmbH (November 2000).
<i>L</i>	AT	<u>26</u>	Röttschke, O., et al., "Superactivation of an immune response triggered by oligomerized T cell epitopes," <i>Proc. Natl. Acad. Sci. USA</i> 94:14642-14647, National Academy of Sciences (1997).

EXAMINER <i>William D. Klemm</i>	DATE CONSIDERED <i>5 28 03</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



FORM PTO-1449 <u>SECOND SUPPLEMENTAL</u> <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1821.0020001/EKS/AJK	APPLICATION NO. 09/833,203
	APPLICANT Zauderer et al.	
	FILING DATE April 12, 2001	GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	27	Röttschke, O., et al., "Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes," <i>Proc. Natl. Acad. Sci. USA</i> 96:7445-7450, National Academy of Sciences (June 1999).
AS		
AT		

EXAMINER

Wm D. Elmer

DATE CONSIDERED

5-23-01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JAN 14 2003

Page 1 of 24

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO. 1821.0020001/EKS/AJK
APPLICATION NO. 09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
M	AL1	WO 98/07441	02/26/1998	WIPO			Yes No
	AM1	EP 0 352 761 A2	07/25/1998	Europe			Abstract Yes No
	AN1	WO 97/35991	10/02/1997	WIPO			Yes No
	AO1	WO 99/21572	05/06/1999	WIPO			Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

M	AR	1	Abdel-Wahab, Z., et al., "Human Dendritic Cells, Pulsed with either Melanoma Tumor Cell Lysates or the gp100 Peptide ⁽²⁸⁰⁻²⁸⁸⁾ , Induce Pairs of T-Cell Cultures with Similar Phenotype and Lytic Activity," <i>Cell. Immunol.</i> 186:63-74, Academic Press (1998).
	AS	1	Alexander, J., et al., "Recognition of a Novel Naturally Processed, A2 Restricted, HCV-NS4 Epitope Triggers IFN-gamma Release in Absence of Detectable Cytopathicity," <i>Hum. Immunol.</i> 59:776-782, Elsevier Science, Inc. (1998).
	AT	1	Alexander, M., et al., "Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope," <i>Am. J. Obstet. Gynecol.</i> 175:1586-1593, Mosby-Year Book, Inc. (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644

RECEIVED

JAN 10 2003

TECH CENTER 100

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	2	Altman, J.D., et al., "Phenotypic Analysis of Antigen-Specific T Lymphocytes," <i>Science</i> 274:94-96, American Association for the Advancement of Science (1996).
AS	2	Battegay, M., et al., "Patients with Chronic Hepatitis C Have Circulating Cytotoxic T Cells Which Recognize Hepatitis C Virus-Encoded Peptides Binding to HLA-A2.1 Molecules," <i>J. Virol.</i> 69:2462-2470, American Society for Microbiology (1995).
AT	2	Bedzyk, W.D., et al., "Immunological and Structural Characterization of a High Affinity Anti-fluorescein Single-chain Antibody," <i>J. Biol. Chem.</i> 265:18615-18620, The American Society for Biochemistry and Molecular Biology, Inc. (1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JAN 10 2003

TECH CENTER 1600-2900

Page 3 of 24

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer *et al.*FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	Bertoletti, A, <i>et al.</i> , "Molecular Features of the Hepatitis B Virus Nucleocapsid T-Cell Epitope 18-27: Interaction with HLA and T-Cell Receptor," <i>Hepatology</i> 26:1027-1034, American Association for the Study of Liver Diseases (1997).
	AS	<u>3</u>	Bocchia, M., <i>et al.</i> , "Specific Human Cellular Immunity to bcr-abl Oncogene-Derived Peptides," <i>Blood</i> 87:3587-3592, The American Society of Hematology (1996).
	AT	<u>3</u>	Bocchia, M., <i>et al.</i> , "Specific Binding of Leukemia Oncogene Fusion Protein Peptides to HLA Class I Molecules," <i>Blood</i> 85:2680-2684, The American Society of Hematology (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JAN 10 2003

TECH CENTER 1600-2001

Page 4 of 24

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Ar	AR	4	Boitel, B., et al., "Strong Similarities in Antigen Fine Specificity Among DRB1*1302-Restricted Tetanus Toxin tt830-843-Specific TCRs in Spite of Highly Heterogeneous CDR3," J. Immunol. 154:3245-3255, The American Association of Immunologists (1995).
I	AS	4	Boniface, J.J., et al., "Initiation of Signal Transduction through the T Cell Receptor Requires the Peptide Multivalent Engagement of MHC Ligands," Immunity 9:459-466, Cell Press (1998).
I	AT	4	Brinckerhoff, L.H., et al., "Terminal Modifications Inhibit Proteolytic Degradation of an Immunogenic Mart-1 ₂₇₋₃₅ Peptide: Implications for Peptide Vaccines," Int. J. Cancer 83:326-334, Wiley-Liss, Inc. (October 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer *et al.*FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Burrows, G.G., <i>et al.</i> , "Two-Domain MHC Class II Molecules Form Stable Complexes with Myelin Basic Protein 69-89 Peptide That Detect and Inhibit Rat Encephalitogenic T Cells and Treat Experimental Autoimmune Encephalomyelitis," <i>J. Immunol.</i> 161:5987-5996, The American Association of Immunologists (1988).
	AS	<u>5</u>	Casares, S., <i>et al.</i> , "Antigen-specific Signaling by a Soluble, Dimeric Peptide/Major Histocompatibility Complex Class II/Fc Chimera Leading to T Helper Cell Type 2 Differentiation," <i>J. Exp. Med.</i> 190:543-553, The Rockefeller University Press (August 1999).
	AT	<u>5</u>	Castelli, C., <i>et al.</i> , "Novel HLA-Cw8-Restricted T Cell Epitopes Derived from Tyrosinase-Related Protein-2 and gp100 Melanoma Antigens," <i>J. Immunol.</i> 162:1739-1748, The American Association of Immunologists (February 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JAN 10 2003

TECH CENTER 1600/2900

Page 6 of 24

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

2	AR	6	Celis, E., et al., "Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five Common HLA-A Alleles," <i>Mol. Immunol.</i> 31:1423-1430, Elsevier Science, Ltd. (1994).
1	AS	6	Chaux, P., et al., "Identification of Mage-3 Epitopes Presented by HLA-DR Molecules to CD4 ⁺ T Lymphocytes," <i>J. Exp. Med.</i> 189:767-777, The Rockefeller University Press (March 1999).
1	AT	6	Chikamatsu, K., et al., "Generation of Anti-p53 Cytotoxic T Lymphocytes from Human Peripheral Blood Using Autologous Dendritic Cells," <i>Clin. Cancer Res.</i> 5:1281-1288, The American Association for Cancer Research (June 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

32	AR	7	Cochran, J.R., et al., "The Relationship of MHC-Peptide Binding and T Cell Activation Probed Using Chemically Defined MHC Class II Oligomers," <i>Immunity</i> 12:241-250, Cell Press (March 2000).
↓	AS	7	Dal Porto, J., et al., "A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations," <i>Proc. Natl. Acad. Sci. USA</i> 90:6671-6675, The National Academy of Sciences (1993).
↓	AT	7	De Backer, O., et al., "Characterization of the GAGE Genes that are Expressed in Various Human Cancers and in Normal Testis," <i>Cancer Res.</i> 59:3157-3165, The American Association for Cancer Research (July 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JAN 10 2003

TECH CENTER 1600-2000

Page 8 of 24

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1821.0020001/EKS/AJK

APPLICATION NO.
09/833,203

APPLICANT
Zauderer et al.

FILING DATE
April 12, 2001

GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	8	Diepolder, H.M., et al., "Immunodominant CD4 ⁺ T-Cell Epitope within Nonstructural Protein 3 in Acute Hepatitis C Virus Infection," <i>J. Virol.</i> 71:6011-6019, American Society for Microbiology (1997).
AS	8	Doolan, D.L., et al., "Degenerate Cytotoxic T Cell Epitopes from <i>P. falciparum</i> Restricted by Multiple HLA-A and HLA-B Supertype Alleles," <i>Immunity</i> 7:97-112, Cell Press (1997).
AT	8	Fleischhauer, K., et al., "Functional Heterogeneity of HLA-A*02 Subtypes Revealed by Presentation of a MAGE-3-Encoded Peptide to Cytotoxic T Cell Clones," <i>J. Immunol.</i> 159:2513-2521, The American Association of Immunologists (1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	2	Esser, S., et al., "Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells," <i>J. Cell Sci.</i> 111:1853-1865, The Company of Biologists Limited (1998).
AS	2	Gotch, F., et al., "Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2," <i>Nature</i> 32:881-882, Nature Publishing Group (1987).
AT	2	Greten, T.F., et al., "Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8 ⁺ T Cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients," <i>Proc. Natl. Acad. Sci. USA</i> 95:7568-7573, The National Academy of Sciences (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Am	AR	<u>10</u>	Hamad, A.R.A., et al., "Potent T Cell Activation with Dimeric Peptide-Major Histocompatibility Complex Class II Ligand: The Role of CD4 Coreceptor," <i>J. Exp. Med.</i> 188: 1633-1640, The Rockefeller University Press (1998).
	AS	<u>10</u>	Harbury, P.B., et al., "A Switch between Two-, Three-, and Four-Stranded Coiled Coils in GCN4 Leucine Zipper Mutants," <i>Science</i> 262:1401-1407, American Association for the Advancement of Science (1993).
↓	AT	<u>10</u>	Harvill, E.T., et al., "In Vivo Properties of an IgG3-IL-2 Fusion Protein," <i>J. Immunol.</i> 157:3165-3170, The American Association of Immunologists (1996).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	11	Heathcote, J., et al., "A Pilot Study of the CY-1899 T-Cell Vaccine in Subjects Chronically Infected with Hepatitis B Virus," <i>Hepatology</i> 30:531-536, The American Association of the Study of Liver Diseases (August 1999).
AS	11	Höllsberg, P., et al., "Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand," <i>Proc. Natl. Acad. Sci. USA</i> 92:4036-4040, National Academy of Sciences (1995).
AT	11	Kawashima, I., et al., "Identification of GP100-Derived, Melanoma-Specific Cytotoxic T-Lymphocyte Epitopes Restricted By HLA-A3 Supertype Molecules By Primary In Vitro Immunization With Peptide-Pulsed Dendritic Cells," <i>Int. J. Cancer</i> 75:518-524, Wiley-Liss, Inc. (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	Kawashima, I., et al., "Identification of HLA-A3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2/ neu by Primary in Vitro Immunization with Peptide-pulsed Dendritic Cells," <i>Cancer Res.</i> 59:431-435, The American Association for Cancer Research (January 1999).
	AS	<u>12</u>	Kim, J., et al., "Determinants of T Cell Reactivity to the <i>Mycobacterium leprae</i> GroES Homologue," <i>J. Immunol.</i> 159:335-343, The American Association of Immunologists (1997).
	AT	<u>12</u>	Kono, K., et al., "Identification of HER2/neu-Derived Peptide Epitopes Recognized by Gastric Cancer-Specific Cytotoxic T Lymphocytes," <i>Int. J. Cancer</i> 78:202-208, Wiley-Liss, Inc. (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Sm	AR	<u>13</u>	Kundu, S.K., et al., "Role of Preimmunization Virus Sequences in Cellular Immunity in HIV-Infected Patients during HIV Type 1 MN Recombinant gp 160 Immunization," <i>Aids Res. Hum. Retroviruses</i> 14:1669-1678, Mary Ann Liebert, Inc. (1998).
	AS	<u>13</u>	Livingston, B.D., et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination are Comparable to Those Elicited by Acute Viral Infection," <i>J. Immunol.</i> 159:1383-1392, The American Association of Immunologists (1997).
↓	AT	<u>13</u>	Manici, S., et al., "Melanoma Cells Present a MAGE-3 Epitope to CD4 ⁺ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11," <i>J. Exp. Med.</i> 189:871-876, The Rockefeller University Press (March 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

30	AR	14	Morrison, S.L., et al., "Production and Characterization of Genetically Engineered Antibody Molecules," <i>Clin. Chem.</i> 34:1668-1675, Journal of the American Association for Clinical Chemistry, Inc. (1988).
↓	AS	14	Nukaya, I., et al., "Identification Of HLA-A24 Epitope Peptides Of Carcinoembryonic Antigen which Induce Tumor-Reactive Cytotoxic Lymphocyte," <i>Int. J. Cancer</i> 80:92-97, Wiley-Liss, Inc. (January 1999).
↓	AT	14	Pack, P., et al., "Tetavalent Miniantibodies with High Avidity Assembling in <i>Escherichia Coli</i> ," <i>J. Mol. Biol.</i> 246:28-34, Academic Press Limited (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	15	Parham, P., et al., "Carbohydrate Moiety of HLA Antigens," <i>J. Biol. Chem.</i> 252:7555-7567, The American Society of Biological Chemists, Inc. (1977).
AS	15	Parkhurst, M.R., et al., "Identification of a Shared HLA-A*0201-restricted T-Cell Epitope from the Melanoma Antigen Tyrosinase-related Protein 2 (TRP2)," <i>Cancer Res.</i> 58:4895-4901, The American Association for Cancer Research (1998).
AT	15	Peiper, M., et al., "Pancreatic Cancer Associated Ascites-Derived CTL Recognize a Nine-Amino-Acid Peptide GP2 Derived from HER2/neu," <i>Anticancer Res.</i> 19:2471-2476, International Institute Anticancer Research (July-August 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Am	AR	16	Penichet, M.L., et al., "An Antibody-Avidin Fusion Protein Specific for the Transferrin Receptor Serves as a Delivery Vehicle for Effective Brain Targeting: Initial Applications in Anti-HIV Antisense Drug Delivery to the Brain," <i>J. Immunol.</i> 163:4421-4426, The American Association of Immunologists (October 1999).
	AS	16	Ressing, M.E., et al., "Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides," <i>J. Immunol.</i> 154:5934-5943, The American Association of Immunologists (1995).
	AT	16	Rivoltini, L., et al., "A Superagonist Variant of Peptide MART1/Melan A ₂₇₋₃₅ Elicits Anti-Melanoma CD8 ⁺ T Cells with Enhanced Functional Characteristics: Implication for More Effective Immunotherapy," <i>Cancer Res.</i> 59:301-306, The American Association for Cancer Research (January 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

JAN 10 2003

Page 17 of 24

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1821.0020001/EKS/AJKTECH CENTER 1000 2900
APPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	17	Rongcun, Y., et al., "Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogenic Carcinomas and Melanomas," <i>J. Immunol.</i> 163:1037-1044, The American Association of Immunologists (July 1999).
AS	17	Salazar-Onfray, F., et al., "Synthetic Peptides Derived from the Melanocyte-stimulating Hormone Receptor MCLR Can Stimulate HLA-A2-restricted Cytotoxic T Lymphocytes That Recognize Naturally Processed Peptides on Human Melanoma Cells," <i>Cancer Res.</i> 57:4348-4355, The American Association for Cancer Research (1997).
AT	17	Schmitt, L., et al., "Catalysis of peptide dissociation from Class II MHC-peptide complexes," <i>Proc. Natl. Acad. Sci. USA</i> 96:6581-6586, The National Academy of Sciences (June 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer *et al.*FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

57	AR	18	Shin, S.-U., <i>et al.</i> , "Functional and Pharmacokinetic Properties of Antibody-Avidin Fusion Proteins," <i>J. Immunol.</i> 158:4797-4804, The American Association of Immunologists (1997).
1	AS	18	Shin, S.-U. and Morrison, S.L., "Production and Properties of Chimeric Antibody Molecules," in <i>Methods in Enzymology</i> , Langone, J.J., ed., Academic Press, Inc., New York, pp. 459-477 (1989).
1	AT	18	Springer, T.A. and Strominger, J.L., "Detergent-soluble HLA antigens contain a hydrophilic region at the COOH-terminus and a penultimate hydrophobic region," <i>Proc. Natl. Acad. Sci. USA</i> 73:2481-2485, The National Academy of Sciences (1976).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

2	AR	19	Steller, M.A., et al., "Cell-mediated Immunological Responses in Cervical and Vaginal Cancer Patients Immunized with a Lipidated Epitope of Human Papillomavirus Type 16 E7," Clin. Cancer Res. 4:2103-2109, The American Association for Cancer Research (1998).
1	AS	19	Takahashi, T., et al., "707-AP Peptide Recognized by Human Antibody Induces Human Leukocyte Antigen A2-restricted Cytotoxic T Lymphocyte Killing of Melanoma," Clin. Cancer Res. 3:1363-1730, The American Association for Cancer Research (1997).
2	AT	19	Takahashi, T., et al., "Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast Cancer," British J. Cancer 81:342-349, Cancer Research Campaign (September 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

in	AR	20	Tanzarella, S., et al., "Identification of a Promiscuous T-Cell Epitope Encoded by Multiple Members of the MAGE Family," <i>Cancer Res.</i> 59:2668-2674, The American Association for Cancer Research (June 1999).
↓	AS	20	Turkewitz, A.P., et al., "Large-Scale Purification of Murine I-A ^k and I-E ^k Antigens and Characterization of the Purified Proteins," <i>Mol. Immunol.</i> 20:1139-1147, Pergamon Press Ltd. (1983).
↓	AT	20	Turner, M.J., et al., "Purification of Papain-solubilized Histocompatibility Antigens from a Cultured Human Lymphoblastoid Line, RPMI 4265," <i>J. Biol. Chem.</i> 250:4512-4519, The American Society of Biological Chemists, Inc. (1975).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	21	Valmori, D., et al., "Analysis of the Cytolytic T Lymphocyte Response of Melanoma Patients to the Naturally HLA-A*0201-associated Tyrosinase Peptide 368-376," <i>Cancer Res.</i> 59:4050-4055, The American Association for Cancer Research (August 1999).
AS	21	Valmori, D., et al., "Analysis of MAGE-3-specific Cytolytic T Lymphocytes in Human Leukocyte Antigen-A2 Melanoma Patients," <i>Cancer Res.</i> 57:735-741, The American Association for Cancer Research (1997).
AT	21	Valmori, D., et al., "Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic Peptide," <i>J. Immunol.</i> 161:6956-6962, The American Association of Immunologists (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

W	AR	22	Wang, R.-F., et al., "Recognition of an Antigenic Peptide Derived from Tyrosinase-Related Protein-2 by CTL in the Context of HLA-A31 and -A33," <i>J. Immunol.</i> 160:890-897, The American Association of Immunologists (1998).
↓	AS	22	Wizel, B., et al., "HLA-A2-Restricted Cytotoxic T Lymphocyte Responses to Multiple <i>Plasmodium falciparum</i> Sporozoite Surface Protein 2 Epitopes in Sporozoite-Immunized Volunteers," <i>J. Immunol.</i> 155:766-775, The American Association of Immunologists (1995).
↓	AT	22	Wizel, B., et al., "Human Infection with <i>Trypanosoma cruzi</i> Induces Parasite Antigen-Specific Cytotoxic T Lymphocyte Responses," <i>J. Clin. Invest.</i> 102:1062-1071, The American Society for Clinical Investigation, Inc. (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Ar	AR	23	Zarour, H.M., et al., "Melan-A/MART-1 ₅₁₋₇₃ represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4 ⁺ T Cells," PNAS 97:400-405, The National Academy of Sciences (January 2000).
↓	AS	23	Zarutskie, J.A., et al., "A Conformational Change in the Human Major Histocompatibility Complex Protein HLA-DR1 Induced by Peptide Binding," Biochemistry 38:5878-5887, American Chemical Society (May 1999).
	AT	23	Zhang, H.-f., et al., "Targeting of functional antibody-CD59 fusion proteins to a cell surface," J. Clin. Invest. 103:55-61, The American Society for Clinical Investigation (January 1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1821.0020001/EKS/AJKAPPLICATION NO.
09/833,203APPLICANT
Zauderer et al.FILING DATE
April 12, 2001GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

42	AR	24	Zhu, X., et al., "A Recombinant Single-Chain Human Class II MHC Molecule (HLA-DR1) as a Covalently Linked Heterotrimer of α Chain, β Chain, and antigenic peptide, with immunogenicity <i>in vitro</i> and reduced affinity for bacterial superantigens," <i>Eur. J. Immunol</i> 27:1933-1941, Verlagsgesellschaft (1997).
↓	AS	24	Dialog File 351, Accession No. 8144344, Derwent WPI English language abstract for EP 352 761 A2 (Document AM1).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.